https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r=
CyBv9bezcPT-2BuItTLKIHepbxTbo-2FYbVFPSBekB-2Bmk9X7Kl8shoTE6BsSbYYjHYcOVCrOC=
rjYrJUHPDVbu1NKaBE-3D_qyi_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2=
FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLN=
n-2B6FohpNoV33cwFF0VywZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy94tXHkhgVZrR8tOWfFEa3=
TcTguEBAZULV5Uv0ChVpLboCUAX8ErGBohxDXMRgGarJcDzeHqeXxgFC-2Fn-2BbAC0ITia0N-2=
FFxcn7TKuQb1KjI-2BfwCf-2BSJeR1-2FNB2bqgs-2BsMnou73eTKAh25Oov6Fii8caVd3xQTjf=
ch7xd-2BeAMWO7liQheKdp4SeiGZaEF2jQS11v0hug-3D
** Acquisition of own shares
------------------------------------------------------------
Brussels (Belgium), 19 April 2024 =E2=80=93 20:00 (CEST) =E2=80=93 Regulate=
d information=C2=A0
In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi=
ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB=
=E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose=
s certain information in relation to its Share Repurchase Program 2024.=C2=
=A0
Under this program, UCB has requested a financial intermediary to repurchas=
e up to 1,300,000 UCB shares on its behalf under the terms of a discretiona=
ry mandate agreement with initial validity until 30 June 2024, effective as=
from 02 April 2024, to cover current and future obligations under UCB's Lo=
ng Term Incentive Plans for its personnel.
In the framework of this Share Repurchase Program 2024, UCB repurchased 90,=
751 UCB shares on Euronext Brussels in the period from 12 April 2024 up to =
and including 18 April 2024, as follows:=C2=A0
https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r=
CyBv9bezcPT-2BuItTLKIHepYYZ4oC6FqiyL9RK4lKLxvgzCp3wwI4OcAGQ4JoUI9r8QfCpMxEF=
Uyyx4wyBo1xpW6DQ14-2FZvKSVODZCasWDx-2F3hRQF_2dCLUNbuBjhX746-2FvM63L9Hyn3KnT=
FGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIx=
s8cV3s33SbkEZvEGLNn-2B6FohpNoV33cwFF0VywZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy94t=
XHkhgVZrR8tOWfFEa3TcTguEBAZULV5Uv0ChVpLboCUAUaH5r6Z-2FW5NqMerJ6J-2BqBeqeCNs=
SfVV9VojEkpoq70ckWc48NKShkm7lUCB45Uhcrs6NCZCrfy1vNy-2B-2Bn7h2R7bKk2x-2BH088=
wF-2BwtqdlfA5jAe5pEQnYJ5VChK3jGf2jEqbCXEyT-2BuTuVJNTA-2F8j94-3D
This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUz=
lo7XKIuSly0rC4Oa12rFuiaXNgb0F6L7ybSCidGRlUFwTxzrkzCt6dOMzdZPcjqPbg8jratFLJj=
fTg-3D-3DwVH3_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BI=
fez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV=
33cwFF0VywZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy94tXHkhgVZrR8tOWfFEa3TcTguEBAZULV=
5Uv0ChVpLboCUAbrbaddXOZj7x2KDzoiY99ZFMY6IYrNHA-2BhYPoo6ZNmN7xc1Osu29eHbbLFT=
PCrhznLN-2Fj0oi3NfAouc9wCcWdGD8S8nA7gLDL86pr1PmwZBEabJcXfIMrs4vrgzNU-2BExqj=
A2-2FgMNN7k9MEHdO7KXlM-3D .
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte=C2=A0
T +32 2 559 94 14
Antje.Witte@ucb.com
Corporate Communications
Laurent Schots=C2=A0
T+32 2 559 92 64
laurent.schots@ucb.com =C2=A0=C2=A0 =C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 9,000 peopl=
e in approximately 40 countries, the company generated revenue of =E2=82=AC=
5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Foll=
ow us on Twitter: @UCB_news.
=C2=A0
GenericFile
240419 - Verwerving van eigen aandelen NL Draft 002 (https://u7061146.ct.se=
ndgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIH=
epYYZ4oC6FqiyL9RK4lKLxvgFaHJIb4S-2B61qNMB2c-2BY8Sw7Edoc8CSI6AvLB8R6uybg-3Dd=
wF8_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSa=
z3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33cwFF0Vyw=
ZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy94tXHkhgVZrR8tOWfFEa3TcTguEBAZULV5Uv0ChVpLb=
oCUAbJIzMUhdt0xrbjzOoXZclIULxeOmEOyGHTj0YoBZ6nGNE4-2Fnl321fUWB83G3p-2Bab1-2=
FRs8mJ-2BrLxhrjrHw1COvG8hM-2FbGuwGEQ8pYjNuz5gqnUYT9TAGTpdqms6hywCoW-2BxwDdZ=
4l-2Fc9-2BHMvNSaVdKg-3D GenericFile
240419 - Acquisition actions propres FR Draft 002 (https://u7061146.ct.send=
grid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHep=
YYZ4oC6FqiyL9RK4lKLxvg9R7RqYdNsoZx57-2BMCBINe7S2rO4Efh-2BIoRc0aF-2FMmP4-3Do=
RmL_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSa=
z3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33cwFF0Vyw=
ZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy94tXHkhgVZrR8tOWfFEa3TcTguEBAZULV5Uv0ChVpLb=
oCUAVuYsePNH5M4gRJA717Hz5rq2foBDF9YdTsy5zik0YoLLNFwGtwPsXeKHEN5wUdIZ4wFM0J1=
wUjD3zM1jmTJ7CLPUIORCWWDylgXgm5JRv0Kot1bXZgDvhvMRiR37MhAZ8nkmPAPOxamq1Lgkxd=
8gfU-3D GenericFile
240419 - Acquisition of own shares ENG Draft (https://u7061146.ct.sendgrid.=
net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepYYZ4o=
C6FqiyL9RK4lKLxvgQ8K-2Fp9eDD4HJfP-2FwOiiyfmVuzWiUOsXN8r2FGJKQYso-3DpUpw_2dC=
LUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcE=
W6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33cwFF0VywZiyWp2s=
5gHiKLKCSVU17BNdM-2BjQMRy94tXHkhgVZrR8tOWfFEa3TcTguEBAZULV5Uv0ChVpLboCUAbDc=
mY7O-2BINSYnV4hEy-2FUNPP1civv8T3WGjmNAi4pCg3bQ3nJ6waLhi6Oc79VjFeLq82NgGdrS6=
PnDE7k5DVIHtLAo0r-2FQEr5JVgLEh2JssArYPjscKQBFpyWsVR6jL04gS2PcvA6AYuUPf83rSq=
ch8-3D Image
Chart 1 April 19 2024 (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001=
.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepYYZ4oC6FqiyL9RK4lKLxvgzCp3ww=
I4OcAGQ4JoUI9r8ahIFoXCUigYDAG-2FeJI4lnw-3DcmlL_2dCLUNbuBjhX746-2FvM63L9Hyn3=
KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93Dw=
fIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33cwFF0VywZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy=
94tXHkhgVZrR8tOWfFEa3TcTguEBAZULV5Uv0ChVpLboCUAep-2BQevq6CT29odz48tpFHctum3=
aFymToUWvJ739o-2Bb9KEz5VMlxiMPd5deVMuGUWWByQi9Tj91VaqwAOGn5KEBPZ7wytKxUzARV=
mlzszFTEsLLy6anyorL6GudhyPcBrAf9ic9bCDnyI7LDiB-2FlAG8-3D
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIu=
Sly0rC3nfmD42E6tJ6HwHGmqtXbhtXDlQ2cTEdRpWV-2BrYPIUNuwurjhdgMpIK83hhh217-2BO=
i9yILcLIuhCr6QTkOeeClaRvgwcAZ9PlIfiihDLdkweJ01g42vwL2YFV9Goq66t-2FalIv9vSEQ=
grExehy57yN8-3D6CeN_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2=
nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6F=
ohpNoV33cwFF0VywZiyWp2s5gHiKLKCSVU17BNdM-2BjQMRy94tXHkhgVZrR8tOWfFEa3TcTguE=
BAZULV5Uv0ChVpLboCUAQxM3t1io7ldwb5R9x17kEHFn041ZlLFVYmLYZiC2Fcmh2Y-2FV4Jrhl=
5ke2Qx-2BqxSj75cXGisqcoS1faAweV38auFwMtO9OmUp1O1qIRj40fgVAEuxt0DvJZwNgRYg41=
IYBmhPOMUcayvwiVbvn9-2FFm8-3D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
